S&P 500   5,149.42
DOW   38,790.43
QQQ   437.48
3 Large-Cap Stocks Buying Back Shares Aggressively
Semis, Nvidia Set for Big Moves as GTC Conference Kicks Off
Here’s Why Bitcoin Miners Stopped Rising With Bitcoin Prices
2 Deep Value, High Yield Stocks With a Double-Digit Upside
3 Stocks About to Boom on Unusual Call Option Volume
How major US stock indexes fared Monday, 3/18/2024
Oil Prices Up Again, Should You Buy This Time?
S&P 500   5,149.42
DOW   38,790.43
QQQ   437.48
3 Large-Cap Stocks Buying Back Shares Aggressively
Semis, Nvidia Set for Big Moves as GTC Conference Kicks Off
Here’s Why Bitcoin Miners Stopped Rising With Bitcoin Prices
2 Deep Value, High Yield Stocks With a Double-Digit Upside
3 Stocks About to Boom on Unusual Call Option Volume
How major US stock indexes fared Monday, 3/18/2024
Oil Prices Up Again, Should You Buy This Time?
S&P 500   5,149.42
DOW   38,790.43
QQQ   437.48
3 Large-Cap Stocks Buying Back Shares Aggressively
Semis, Nvidia Set for Big Moves as GTC Conference Kicks Off
Here’s Why Bitcoin Miners Stopped Rising With Bitcoin Prices
2 Deep Value, High Yield Stocks With a Double-Digit Upside
3 Stocks About to Boom on Unusual Call Option Volume
How major US stock indexes fared Monday, 3/18/2024
Oil Prices Up Again, Should You Buy This Time?
S&P 500   5,149.42
DOW   38,790.43
QQQ   437.48
3 Large-Cap Stocks Buying Back Shares Aggressively
Semis, Nvidia Set for Big Moves as GTC Conference Kicks Off
Here’s Why Bitcoin Miners Stopped Rising With Bitcoin Prices
2 Deep Value, High Yield Stocks With a Double-Digit Upside
3 Stocks About to Boom on Unusual Call Option Volume
How major US stock indexes fared Monday, 3/18/2024
Oil Prices Up Again, Should You Buy This Time?
NASDAQ:BOLT

Bolt Biotherapeutics (BOLT) Stock Price, News & Analysis

$1.14
+0.03 (+2.70%)
(As of 03/18/2024 ET)
Today's Range
$1.10
$1.17
50-Day Range
$1.01
$1.33
52-Week Range
$0.84
$2.03
Volume
100,362 shs
Average Volume
117,303 shs
Market Capitalization
$43.29 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$7.00

Bolt Biotherapeutics MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
514.0% Upside
$7.00 Price Target
Short Interest
Bearish
7.27% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.30mentions of Bolt Biotherapeutics in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
N/A

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.85 out of 5 stars

Medical Sector

582nd out of 947 stocks

Pharmaceutical Preparations Industry

272nd out of 435 stocks

BOLT stock logo

About Bolt Biotherapeutics Stock (NASDAQ:BOLT)

Bolt Biotherapeutics, Inc., a clinical-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer. The company's lead product candidate BDC-1001, which is in Phase II clinical trial for the treatment of patients with human epidermal growth factor receptor 2- positive solid tumors, including breast, colorectal, endometrial, and gastroesophageal cancer. It is also developing BDC-2034, an agonist antibody targeting Dectin-2 for range of tumors, such as head and neck, non-small cell lung, ovarian, triple-negative breast, and other cancer. The company has collaboration agreements with Toray Industries, Genmab A/S, Innovent Biologics, Inc., Bristol-Myers Squibb, and F. Hoffmann-La Roche Ltd; and license agreement with Stanford University. The company was formerly known as Bolt Therapeutics, Inc. and changed its name to Bolt Biotherapeutics, Inc. in July 2015. Bolt Biotherapeutics, Inc. was incorporated in 2015 and is headquartered in Redwood City, California.

BOLT Stock Price History

BOLT Stock News Headlines

They said crypto was dead. It went up 100X.
Bitcoin’s haters are out again. Despite the price doubling in the last six months alone… That hasn’t stopped the experts from piling on. Warren Buffett’s right-hand man Charlie Munger called crypto investors “idiots” in one of his last interviews. JPMorgan CEO Jamie Dimon, recently called Bitcoin a “pet rock” and “a hyped-up fraud.” But when it comes to cryptos, these are exactly the people you shouldn’t listen to. They’ve predicted crypto’s demise for years.
Bolt Biotherapeutics Inc Ordinary Shares BOLT
The AI Bottleneck No One is Talking About
Renewable energy is growing at an impressive speed - but not fast enough. This could be one of the greatest periods for the nuclear industry ever.
US0977021049.SG - Bolt Biotherapeutics Inc.
Bolt Biotherapeutics (BOLT) Receives a Buy from H.C. Wainwright
BOLT.O - | Stock Price & Latest News | Reuters
See More Headlines
Receive BOLT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Bolt Biotherapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/08/2021
Today
3/18/2024
Next Earnings (Estimated)
4/03/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:BOLT
CUSIP
09769810
Fax
N/A
Employees
94
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$7.00
High Stock Price Target
$8.00
Low Stock Price Target
$6.00
Potential Upside/Downside
+514.0%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Net Income
$-88,100,000.00
Net Margins
-990.43%
Pretax Margin
-990.43%

Debt

Sales & Book Value

Annual Sales
$5.73 million
Book Value
$4.55 per share

Miscellaneous

Free Float
27,184,000
Market Cap
$43.29 million
Optionable
Not Optionable
Beta
0.93
The Next 7 Blockbuster Stocks for Growth Investors Cover

Wondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.

Get This Free Report

Key Executives

  • Dr. Randall C. Schatzman Ph.D. (Age 69)
    CEO & Director
    Comp: $829.32k
  • Dr. Edgar George Engleman M.D. (Age 78)
    Founder & Independent Director
    Comp: $38.75k
  • Mr. William P. QuinnMr. William P. Quinn (Age 53)
    CFO & Secretary
    Comp: $594.56k
  • Mr. Grant Yonehiro C.F.A. (Age 60)
    M.B.A., Chief Business Officer
    Comp: $544.71k
  • Dr. Edith A. Perez M.D. (Age 67)
    Chief Medical Officer
    Comp: $668.32k
  • Mr. Wesley Burwell
    VP & Head of Human Resources
  • Dr. Nathan Ihle Ph.D.
    Senior Vice President of Pharmaceutical Operations

BOLT Stock Analysis - Frequently Asked Questions

Should I buy or sell Bolt Biotherapeutics stock right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Bolt Biotherapeutics in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" BOLT shares.
View BOLT analyst ratings
or view top-rated stocks.

What is Bolt Biotherapeutics' stock price target for 2024?

2 equities research analysts have issued 12 month price objectives for Bolt Biotherapeutics' stock. Their BOLT share price targets range from $6.00 to $8.00. On average, they expect the company's share price to reach $7.00 in the next twelve months. This suggests a possible upside of 514.0% from the stock's current price.
View analysts price targets for BOLT
or view top-rated stocks among Wall Street analysts.

How have BOLT shares performed in 2024?

Bolt Biotherapeutics' stock was trading at $1.12 on January 1st, 2024. Since then, BOLT stock has increased by 1.8% and is now trading at $1.14.
View the best growth stocks for 2024 here
.

Are investors shorting Bolt Biotherapeutics?

Bolt Biotherapeutics saw a increase in short interest in February. As of February 29th, there was short interest totaling 1,740,000 shares, an increase of 7.4% from the February 14th total of 1,620,000 shares. Based on an average trading volume of 127,100 shares, the days-to-cover ratio is presently 13.7 days. Approximately 7.3% of the shares of the stock are short sold.
View Bolt Biotherapeutics' Short Interest
.

When is Bolt Biotherapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, April 3rd 2024.
View our BOLT earnings forecast
.

How were Bolt Biotherapeutics' earnings last quarter?

Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) posted its earnings results on Monday, November, 8th. The company reported ($0.63) earnings per share for the quarter, beating the consensus estimate of ($0.75) by $0.12. The firm earned $0.75 million during the quarter, compared to analysts' expectations of $1.50 million. Bolt Biotherapeutics had a negative net margin of 990.43% and a negative trailing twelve-month return on equity of 47.56%.

What other stocks do shareholders of Bolt Biotherapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Bolt Biotherapeutics investors own include Allena Pharmaceuticals (ALNA), Ampliphi Biosciences (APHB), Arbutus Biopharma (ABUS), Aurora Cannabis (ACBFF), AcelRx Pharmaceuticals (ACRX), Aldeyra Therapeutics (ALDX), Apellis Pharmaceuticals (APLS), Aquinox Pharmaceuticals (AQXP).

When did Bolt Biotherapeutics IPO?

(BOLT) raised $150 million in an initial public offering (IPO) on Friday, February 5th 2021. The company issued 8,800,000 shares at $16.00-$18.00 per share. Morgan Stanley, SVB Leerink, Stifel and Guggenheim Securities acted as the underwriters for the IPO.

Who are Bolt Biotherapeutics' major shareholders?

Bolt Biotherapeutics' stock is owned by a variety of retail and institutional investors. Top institutional investors include Vivo Capital LLC (9.27%), Citadel Advisors LLC (6.48%), Newtyn Management LLC (4.09%), Board of Trustees of The Leland Stanford Junior University (1.90%) and Northern Trust Corp (0.11%). Insiders that own company stock include Edgar Engleman, Holdings A/S Novo, Vivo Capital Viii, Llc and William P Quinn.
View institutional ownership trends
.

How do I buy shares of Bolt Biotherapeutics?

Shares of BOLT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:BOLT) was last updated on 3/19/2024 by MarketBeat.com Staff

From Our Partners